이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Medtronic 관리

관리 기준 확인 4/4

Medtronic's CEO는 Geoff Martha, Apr2020 에 임명되었습니다 의 임기는 4.17 년입니다. 총 연간 보상은 $ 15.39M, 8.8% 로 구성됩니다. 8.8% 급여 및 91.2% 보너스(회사 주식 및 옵션 포함). 는 $ 11.43M 가치에 해당하는 회사 주식의 0.011% 직접 소유합니다. 11.43M. 경영진과 이사회의 평균 재임 기간은 각각 3.4 년과 9.4 년입니다.

주요 정보

Geoff Martha

최고 경영자

US$15.4m

총 보상

CEO 급여 비율	8.8%
CEO 임기	4.2yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	3.4yrs
이사회 평균 재임 기간	9.4yrs

최근 관리 업데이트

Recent updates

Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70

May 26

These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well

May 22

Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release

May 13

Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?

May 01

35% Undervalued? Medtronic's Future Looks Very Bright

Apr 12

Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now

Mar 27

Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth

Mar 11

Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69

Mar 11

Medtronic: Its Recent Beat Proves That It Continues To Be A Rock

Feb 25

Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts

Feb 22

Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility

Feb 16

A Look At The Fair Value Of Medtronic plc (NYSE:MDT)

Jan 31

Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?

Jan 16

Medtronic Stock's Rally Is Set To Continue

Jan 11

Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings

Dec 29

Medtronic's (NYSE:MDT) Dividend Will Be $0.69

Dec 12

Medtronic: The GLP-1 Drug Headwinds Are Overblown

Dec 10

3.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic

Nov 28

Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes

Nov 19

Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings

Nov 17

Medtronic Faces Potential Decline Despite Financial Strength

Oct 29

An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued

Oct 19

Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly

Oct 04

Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%

Sep 27

Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69

Sep 18

Medtronic: The Tide Is Turning

Aug 24

Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69

Aug 21

Medtronic: Dark Clouds Are Clearing - Outperformance Ahead

Aug 14

Return Trends At Medtronic (NYSE:MDT) Aren't Appealing

Aug 11

Medtronic: Expanding Product Portfolio Without Affecting Dividend Growth

Jul 15

Are Medtronic plc (NYSE:MDT) Investors Paying Above The Intrinsic Value?

Jul 09

Is Medtronic (NYSE:MDT) A Risky Investment?

Jun 21

Medtronic: Weak Forecasts Spoiled Strong Results For The Reporting Quarter

Jun 21

Is Medtronic's Dividend In A Good Place?

Jun 14

Medtronic (NYSE:MDT) Is Increasing Its Dividend To $0.69

Jun 03

Medtronic: Solid Q4 Earnings, Don't Fret About Guidance

May 26

CEO 보상 분석

Geoff Martha 의 보수는 Medtronic 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Apr 26 2024	n/a	n/a	US$4b
Jan 26 2024	n/a	n/a	US$4b
Oct 27 2023	n/a	n/a	US$4b
Jul 28 2023	n/a	n/a	US$4b
Apr 28 2023	US$15m	US$1m	US$4b
Jan 27 2023	n/a	n/a	US$4b
Oct 28 2022	n/a	n/a	US$4b
Jul 29 2022	n/a	n/a	US$5b
Apr 29 2022	n/a	n/a	US$5b
Jan 28 2022	n/a	n/a	US$5b
Oct 29 2021	n/a	n/a	US$5b
Jul 30 2021	n/a	n/a	US$4b
Apr 30 2021	US$18m	US$1m	US$4b
Jan 29 2021	n/a	n/a	US$3b
Oct 30 2020	n/a	n/a	US$4b
Jul 31 2020	n/a	n/a	US$4b
Apr 24 2020	US$6m	US$905k	US$5b
Jan 24 2020	n/a	n/a	US$5b
Oct 25 2019	n/a	n/a	US$5b
Jul 26 2019	n/a	n/a	US$4b
Apr 26 2019	US$4m	US$693k	US$5b

보상 대 시장: Geoff 의 총 보상 ($USD 15.39M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 13.50M ).

보상과 수익: Geoff 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Geoff Martha (54 yo)

4.2yrs

테뉴어

US$15,394,632

보상

Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Chairman at Medtron...

리더십 팀

이름	위치	테뉴어	보상	소유권
Geoffrey Martha	Chairman of the Board & CEO	4.2yrs	US$15.39m	0.011% $ 11.3m
Karen Parkhill	Executive VP & CFO	8yrs	US$6.12m	0.0052% $ 5.2m
Sean Salmon	Executive VP & President of Cardiovascular Portfolio	no data	US$5.36m	0.0019% $ 1.9m
Robert J. ten Hoedt	Executive VP & President of Global Regions	9.4yrs	US$5.05m	0.0024% $ 2.5m
Mark Ploof	Senior Vice President of Global Operations and Business Services	7.7yrs	데이터 없음	데이터 없음
Jennifer Kirk	Senior VP	3yrs	데이터 없음	0.0010% $ 1.0m
Kenneth Washington	Senior VP and Chief Technology & Innovation Officer	less than a year	데이터 없음	데이터 없음
Laura Mauri	Senior VP and Chief Scientific & Medical Officer	2.2yrs	데이터 없음	데이터 없음
Ryan Weispfenning	VP & Head of Investor Relations	9yrs	데이터 없음	데이터 없음
Ivan Fong	Executive VP	2.3yrs	US$11.72m	0.00085% $ 857.9k
Torod Neptune	Senior VP & Chief Communications Officer	3.4yrs	데이터 없음	데이터 없음
Matt Walter	Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: MDT 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Geoffrey Martha	Chairman of the Board & CEO	4.6yrs	US$15.39m	0.011% $ 11.3m
Scott Donnelly	Independent Director	11.4yrs	US$365.01k	0.0014% $ 1.4m
Kendall Powell	Independent Director	17.4yrs	US$350.01k	0.0034% $ 3.4m
Randall Hogan	Independent Director	9.4yrs	US$385.01k	0.0034% $ 3.4m
Craig Arnold	Lead Independent Director	9.4yrs	US$410.01k	0.0028% $ 2.8m
Denise O'Leary	Independent Director	24.4yrs	US$375.01k	0.0060% $ 6.1m
Andrea Goldsmith	Independent Director	5.3yrs	US$370.01k	0.00048% $ 484.5k
Elizabeth Nabel	Independent Director	10.4yrs	US$370.01k	0.0010% $ 1.1m
Lidia Fonseca	Independent Director	2yrs	US$294.37k	0.00012% $ 121.1k
Kevin Lofton	Independent Director	3.8yrs	US$370.01k	0.00032% $ 323.0k
Gregory Lewis	Independent Director	less than a year	데이터 없음	데이터 없음

9.4yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: MDT 의 이사회는 경험(평균 재직 기간 9.4 년)으로 간주됩니다.

Medtronic 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Chairman of the Board & CEO notifies of intention to sell stock

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Insider notifies of intention to sell stock

Medtronic plc Appoints Greg Lewis as New Director

Recent updates

New minor risk - Earnings quality

Now 20% undervalued after recent price drop

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Full year 2024 earnings: EPS misses analyst expectations

Medtronic: Why I Disagree With The Crowd

Chairman of the Board & CEO notifies of intention to sell stock

Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Consensus EPS estimates fall by 10%

Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued

Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70

Full year 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 10%

Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024

These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release

Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

35% Undervalued? Medtronic's Future Looks Very Bright

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now

Upcoming dividend of US$0.69 per share

Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth

Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69

Third quarter dividend of US$0.69 announced

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Medtronic: Its Recent Beat Proves That It Continues To Be A Rock

Insider notifies of intention to sell stock

Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

A Look At The Fair Value Of Medtronic plc (NYSE:MDT)

Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?

Medtronic Stock's Rally Is Set To Continue

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Medtronic's (NYSE:MDT) Dividend Will Be $0.69

Upcoming dividend of US$0.69 per share at 3.5% yield

Medtronic: The GLP-1 Drug Headwinds Are Overblown

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

3.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes

Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings

Medtronic Faces Potential Decline Despite Financial Strength

Now 21% undervalued after recent price drop

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued

Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly

Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69

Upcoming dividend of US$0.69 per share at 3.4% yield

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic: The Tide Is Turning

Medtronic plc Raises Earnings Guidance for 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69